Medical Microbiology, Department of Laboratory Medicine Malmö, Lund University, Skåne University Hospital, Malmö, Sweden.
Swiss Med Wkly. 2012 Oct 29;142:w13694. doi: 10.4414/smw.2012.13694. eCollection 2012.
Moraxella catarrhalis (M. catarrhalis) is a human-restricted commensal of the normal bacterial flora in the upper respiratory tract of children, and - during the previous two decades - has been recognised as a true human pathogen. M. catarrhalis is the third most common pathogen causing acute otitis media in children, which is the most common reason to visit a paediatrician during childhood. Acute otitis media thus causes a high clinical and economical burden. With the introduction of the conjugate pneumococcal vaccines the microbiomic pattern in the nasopharyngeal flora of children has changed, and the frequency of isolation of M. catarrhalis has increased. Compared to adults, children are more often colonised with M. catarrhalis. Over the last three decades there has been a dramatic increase in the acquisition of β-lactam resistance in M. catarrhalis. Today 95-100% of clinically isolated M. catarrhalis produce β-lactamase. It is thus desirable to reduce the burden of M. catarrhalis disease by developing a vaccine. There are several potential vaccine antigen candidates in different stages of development, but none of them has entered clinical trials at the present time.
卡他莫拉菌(M. catarrhalis)是儿童上呼吸道正常菌群中的一种人类限制性共生菌,在过去的二十年中,它已被确认为一种真正的人类病原体。卡他莫拉菌是导致儿童急性中耳炎的第三大常见病原体,这也是儿童在童年时期最常去看儿科医生的原因。因此,急性中耳炎给临床和经济带来了巨大负担。随着结合型肺炎球菌疫苗的引入,儿童鼻咽菌群中的微生物组模式发生了变化,卡他莫拉菌的分离频率增加。与成年人相比,儿童更容易被卡他莫拉菌定植。在过去的三十年中,卡他莫拉菌对β-内酰胺类药物的耐药性急剧增加。如今,95-100%的临床分离的卡他莫拉菌产生β-内酰胺酶。因此,通过开发疫苗来降低卡他莫拉菌病的负担是很有必要的。有几个潜在的疫苗抗原候选物处于不同的开发阶段,但目前没有一个进入临床试验。